Heart failure drug study pulled before it started

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Man or woman over the age of 18 years. * Willing and able to sign the informed consent. * A clinical diagnosis of chronic HF that is considered by patient's cardiologist/physician to be stable over the one-month period prior to randomization. * Receiving a stable dose of furosemide of 40mg or 80mg total per day (or equivalent doses of torsemide or bumetanide) for at least 30 days prior to randomization. * Optimum volume status determined by experienced physician. * Able to consume a diet containing approximately 3 grams of Na+ daily. * No anticipated changes in HF medications during the study period. Exclusion Criteria: * Requirement for a diuretic other than furosemide, bumetanide or torsemide except for spironolactone, eplerenone, finerenone, or SGLT2 inhibitors, given in stable dose for \> 2 weeks before randomization and during the study. * Known non-adherence to medication intake or salt restriction. * Myocardial infarction, stroke, transient ischemic attack, acute kidney injury or acute HF requiring admission to hospital within the last 30 days prior to randomization. * Severe / symptomatic lung disease or respiratory symptoms distinct from HF. * Urinary incontinence or inability to empty bladder with a post-void residual volume \>100 ml. * Uncontrolled diabetes mellitus or uncontrolled hypertension. * Estimated GFR \< 30 ml/min/1.72m2 of body surface area. * Use of any non-loop diuretic in the last 30 days prior to randomization, with the exception of a low dose MRA (e.g., spironolactone of 25-50 mg per day) or an SGLT2 inhibitor. * History of flash pulmonary edema or amyloid cardiomyopathy. * Requirement for a non-steroidal anti-inflammatory drug other than low dose aspirin (\<200 mg daily) * Refusal or inability to sign the informed consent.